China's Minister of Commerce Wang Wentao met with global pharmaceutical leaders in Beijing for a high-level dialogue.
The meeting brought together policymakers and senior executives from multinational drugmakers including Novartis, AstraZeneca, Roche, Boehringer Ingelheim and Organon.
"The pharmaceutical industry is vital to human health, we welcome your views and suggestions on development in China,” Wang said while addressing participants at the high-level dialogue.
Drawing growing global attention, China is now one of the world’s fastest-evolving markets and is signaling openness by inviting deeper engagement from multinational companies already investing in the country, according to U.S. pharmaceutical officials.
"For the innovative pharmaceutical sector, China has become one of the world's largest and fastest evolving markets, playing an increasingly global role," said Stephen J. Ubl, president and chief executive officer of the Pharmaceutical Research and Manufacturers of America (PhRMA).
From cutting-edge biotech to large-scale manufacturing, global firms say China’s appeal lies in its unique combination of scale and capabilities.
"Key factors in this evolution include China's large patient population, scientific talent, clinical research capacity, and investments in science and healthcare," said Ubl.
China’s commerce minister meets global pharma leaders
China’s commerce minister meets global pharma leaders
